Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why
Shares of Amicus Therapeutics, Inc. FOLD have rallied 27.9% in the past three months compared with the industry’s increase of 10.7%. In late September 2023, the FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease (LOPD) in adults who weigh more than 40 ...